ABOUT KITOV


Kitov Pharmaceuticals is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

Kitov's flagship combination drug, KIT-302, aims to treat osteoarthritis pain and hypertension simultaneously. KIT-302 achieved the primary efficacy endpoint for its Phase III clinical trial. A New Drug Application (NDA) was submitted in July 2017 and the U.S. Food and Drug Administration (FDA)  filed the NDA on September 29 2017, thereby accepting the NDA for a full review.

Kitov's newest drug, NT-219, which is developed by its majority-owned subsidiary, TyrNovo, is a small molecule that presents a new concept in cancer therapy. When combined with various approved oncology drugs, NT-219 demonstrated potent anti-tumor effects and increased survival in various cancer models.

By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people's lives.

 

 

 

READ MORE

KIT-302

Combination drug meets primary efficacy
endpoint in Phase III trial


Kitov’s KIT-302 is a combination drug that aims to treat OA pain and HTN simultaneously. In December 2015, it was announced that the Phase III clinical trial for KIT-302 successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Kitov submitted a new drug application (NDA) for marketing approval of KIT-302 with the FDA on July 2017.

 

READ MORE

NT-219

First-in-class small molecule designed
to overcome cancer drug resistance


NT-219 is an innovative, first-in-class small molecule designed to overcome cancer drug resistance. NT-219 targets two proteins involved in the anticancer drug resistance mechanism – IRS1/2 and STAT3. When administered in combination with various oncology therapies in various PDX models, NT-219 demonstrated outstanding efficacy in preventing acquired resistance and reversing tumor resistance. Preliminary synergistic effects were also observed in its combination with immune oncology agents such as Keytruda®.

 

READ MORE